RECOGNITION OF THE METABOLIC SYNDROME
|
|
- Ira Webster
- 5 years ago
- Views:
Transcription
1 THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary heart disease and type 2 diabetes mellitus despite the fact that the risk factors comprising the metabolic syndrome are, for the most part, modifiable through diet, increased physical activity, and the use of medications. The National Cholesterol Education Program's Adult Treatment Panel (ATP) III guidelines recommend lipoprotein analysis (ie, total cholesterol, low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, and triglycerides) as an initial screening test for assessing cardiovascular risk. As a cardinal component of the metabolic syndrome, dyslipidemia is one of the primary targets of management. The choice of interventions for dyslipidemia is guided by the principle that intensity of treatment should be directly related to the degree of risk for coronary heart disease events. According to ATP III guidelines, LDL cholesterol is a primary target of treatment in patients with the metabolic syndrome. Secondary targets are other metabolic syndrome components including other lipid risk factors. Diet and exercise are core components of the management of multiple metabolic syndrome components. LDL-lowering pharmacotherapy is considered (but may not always be required) in patients with LDL levels of 100 mg/dl or higher. Therapy to address atherogenic dyslipidemia (ie, triglycerides 150 mg/dl and HDL cholesterol *Director of Preventive Cardiology, Rush University Medical Center, Chicago, Illinois. Address correspondence to: Michael H. Davidson, MD, Director of Preventive Cardiology, Rush University Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL michaeldavidson@radiantresearch.com. <40 mg/dl) is initiated after the LDL treatment goal is achieved with therapeutic lifestyle changes or pharmacotherapy. Combination therapy with a statin, which is most effective at modifying LDL cholesterol, and a fibrate or niacin, which are more effective for modifying HDL cholesterol and triglyceride, may further reduce the residual risk associated with the mixed dyslipidemia occurring in the metabolic syndrome compared to monotherapy. (Adv Stud Med. 2005;5(6A):S503-S510) Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary heart disease and type 2 diabetes mellitus despite the fact that the risk factors comprising the metabolic syndrome are, for the most part, modifiable through diet, increased physical activity, and the use of medications. This paper discusses clinical management of the metabolic syndrome with particular emphasis on the management of dyslipidemia, one of the core abnormalities in the metabolic syndrome. RECOGNITION OF THE METABOLIC SYNDROME The metabolic syndrome constitutes a cluster of physiologic abnormalities that together confer greater cardiovascular and metabolic risk than that posed by the abnormalities individually. 1 Cardiovascular risk factors including but not limited to being overweight or obese, blood lipid abnormalities, abdominal obesity, and hypertension should alert the healthcare provider to the possible presence of the metabolic syndrome and prompt further assessment to determine whether metabolic and/or cardiovascular intervention Advanced Studies in Medicine S503
2 is warranted. The Adult Treatment Panel III (ATP III) criteria proposed by the National Cholesterol Education Program specify that the metabolic syndrome is present if at least 3 of the following criteria are met: Waist circumference larger than 102 cm in men and larger than 88 cm in women; Serum triglyceride concentration of 150 mg/dl or higher; Serum high-density lipoprotein (HDL) concentration less than 40 mg/dl in men and less than 50 mg/dl in women; Blood pressure of 130/85 mm Hg or higher or therapy with antihypertensive medication; Fasting plasma glucose of 110 mg/dl or higher. 2 The ATP III guidelines recommend an analysis of multiple lipids and lipoproteins (ie, total cholesterol, low-density lipoprotein [LDL] cholesterol, HDL cholesterol, and triglycerides) as an initial screening test for assessing cardiovascular risk. 2 Similarly, the US Preventive Services Task Force recommends that screening for lipid disorders include the measurement of total cholesterol and HDL levels. 3 These recommendations, made in the context of evidence suggesting that the various lipoproteins constitute independent cardiovascular risk factors, contrast with the previously common practice of focusing on LDL as a primary or sole determinant of cardiovascular risk. The ATP III guidelines are useful in identifying patients with the metabolic syndrome, but they may be too restrictive for identifying some at-risk individuals who are candidates for intervention to delay or to prevent type 2 diabetes mellitus and its cardiovascular correlates. Data from one study suggest that application of these criteria would result in missing more than 50% of individuals who are insulin-resistant and may benefit from intervention to prevent cardiovascular disease and type 2 diabetes mellitus. 4 In this study, which enrolled overweight individuals, the most useful metabolic markers for identifying insulin resistance were plasma triglyceride concentration, ratio of triglyceride to HDL cholesterol, and insulin concentration. Optimal cut-points were 130 mg/dl for triglycerides, 3.0 (traditional units) for the triglyceride-hdl cholesterol ratio, and 109 pmol/l for insulin. The presence of one component of the metabolic syndrome heightens the risk of the patient having one or more of the other components, and the degree of health risk associated with the metabolic syndrome is directly related to the number of components present. 1 Although the clustering of risk factors is important in determining the risk status of the patient and in deciding on an intervention strategy, the absence of one or more major risk factors should not be interpreted as reflecting reduced or low cardiovascular or metabolic risk. In a study of 465 healthy volunteers, 36% of the individuals who were most insulin-resistant were also obese; steady-state plasma glucose and body mass index were significantly correlated findings consistent with the clustering of risk factors observed in the metabolic syndrome. 5 However, 16% of the individuals who were most insulin-resistant, thus at high cardiovascular and metabolic risk, were of normal weight. Therefore, although the metabolic syndrome is relatively uncommon in the absence of obesity, the absence of obesity does not signify the absence of metabolic and cardiovascular risk. These data underline the importance of taking into account multiple risk factors in assessing cardiovascular and metabolic risk. FOCUS ON DYSLIPIDEMIA CARDIOVASCULAR RISK ASSESSMENT As a cardinal component of the metabolic syndrome, dyslipidemia is one of the primary targets of management. The choice of interventions for dyslipidemia is guided by the principle that the intensity of treatment should be directly related to the degree of risk for coronary heart disease events. 2 The ATP III report identifies 3 major risk categories (ie, high, intermediate, and low) for coronary heart disease. High risk is defined as the confirmed presence of coronary heart disease or a coronary heart disease risk-equivalent. Coronary heart disease risk-equivalents, so designated because they carry a risk of major coronary events equivalent to that of established coronary heart disease, include diabetes; other clinical forms of atherosclerotic disease (ie, peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease); or the presence of multiple risk factors conferring a greater than 20%, 10-year risk for coronary heart disease. Intermediate risk is defined as the presence of 2 or more risk factors listed in Table 1. 2 Low risk is defined as the presence of 1 or no risk factors. The ATP III report advocates a 2-step procedure for determining risk status in individuals without clin- S504 Vol. 5 (6A) June 2005
3 ically manifest coronary heart disease or other forms of atherosclerotic disease. First, the number of risk factors present is counted. Then, for individuals with 2 or more risk factors, a 10-year risk assessment is calculated based on the Framingham Heart Study scoring to identify those patients whose 10-year risk warrants intervention. This second step is not completed for individuals with 0 or 1 risk factors because they are thought to be at too low a risk to require intervention. The Framingham system considers primary, independent risk factors for the presence of coronary heart disease operationally defined as angina pectoris, recognized myocardial infarction, unrecognized myocardial infarction (defined by electrocardiogram), unstable angina, and coronary heart disease deaths to include cigarette smoking (any amount), elevated systolic blood pressure, elevated serum total cholesterol and LDL cholesterol, low serum HDL cholesterol, diabetes mellitus, and advancing age. 6 As revealed in the Framingham study and other investigations, the relationship between values of these factors and risk of coronary heart disease is continuous. Furthermore, the risk factors confer additive risk of coronary heart disease. Therefore, the total risk for an individual can be estimated by totaling the risks associated with each factor. By using Framingham algorithms, absolute risk (defined as the probability of developing coronary heart disease in a given time period) and relative risk (defined as the risk of coronary heart disease relative to low-risk status) can be calculated. According to the Framingham report, low-risk status is a patient who does not smoke, does not have diabetes, and whose test results show the following values: serum total cholesterol, 160 to 199 mg/dl; LDL cholesterol, 100 to 129 mg/dl; HDL cholesterol, at least 45 mg/dl in men and at least 55 mg/dl in women; and blood pressure, less than 120 mm Hg systolic and less than 80 mm Hg diastolic. 7 American Heart Association guidelines for primary prevention of cardiovascular disease and stroke now recommend that risk-factor screening be conducted every 2 to 5 years beginning at age 20 years and that global risk-factor estimation be conducted every 5 years (or more often, in the presence of changing risk factors) in adults. 8 As patients and healthcare providers increasingly follow this recommendation, more patients will have current cardiovascular risk-status information as part of their medical record. The predictive ability of these and other risk-assessment models may be enhanced by increasing their complexity to include factors such as inflammatory markers, genetic susceptibility, lifestyle, and other variables. 9 The Multi-Ethnic Study of Atherosclerosis is Table 1. Major Risk Factors for Coronary Heart Disease in ATP III Guidelines Cigarette smoking Hypertension (ie, blood pressure >140/90 mm Hg or on antihypertensive medication) High LDL cholesterol (ie, >159 mg/dl) Low HDL cholesterol (ie, <40 mg/dl) Family history of premature coronary heart disease (ie, <55 years of age in male first-degree relative or <65 years of age in female first-degree relative) Age (men at least 45 years and women at least 55 years) ATP = Adult Treatment Panel; HDL = high-density lipoprotein; LDL = lowdensity lipoprotein. Data from Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. September 2002; NIH publication Table 2. LDL Cholesterol Goals by Coronary Heart Disease Risk Level Risk Level LDL-C Goal CHD and CHD Risk Equivalent <100 mg/dl Multiple (2+) Risk Factors <130 mg/dl 0 1 risk factor <160 mg/dl CHD = coronary heart disease; LDL-C = low-density lipoprotein cholesterol. Reprinted from Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. September 2002; NIH publication Advanced Studies in Medicine S505
4 evaluating whether new predictive markers of cardiovascular risk are useful in a National Heart, Lung, and Blood Institute study that involves subjects and is to be completed in THERAPEUTIC GOALS FOR DYSLIPIDEMIA According to ATP III guidelines, LDL cholesterol is the primary target of treatment in patients at cardiovascular risk. 2 Secondary targets are HDL cholesterol and triglycerides. LDL cholesterol also constitutes the primary target of treatment in patients with the metabolic syndrome. Secondary targets in these patients are other metabolic syndrome components including other lipid risk factors. LDL goals by risk category are shown in Table 2. 2 INTERVENTION: LIFESTYLE MODIFICATIONS Diet and exercise are core components of the management of multiple metabolic syndrome components including dyslipidemia. Dietary modifications recommended in ATP III guidelines include reductions in saturated fat, reductions in dietary cholesterol, and weight loss. 2 Reduction of saturated fats to less than 7% of calories, dietary cholesterol to less than 200 mg/day, and weight loss of 10 lbs can result in LDL reductions ranging from 8% to 10%, 3% to 5%, and 5% to 8%, respectively. 2 Weight loss in overweight or obese patients can also decrease triglyceride levels and blood pressure and can improve insulin sensitivity and glucose utilization, in addition to decrease the requirements for insulin therapy or oral hypoglycemics in patients with type 2 diabetes mellitus. Adult Treatment Panel III guidelines emphasize the benefits of exercise, particularly in the management of the metabolic syndrome. 2 Exercise can improve lipid profiles by decreasing triglycerides, total cholesterol, and, in some individuals, LDL cholesterol and by increasing HDL cholesterol. Exercise can also facilitate weight loss and increase insulin sensitivity by lowering blood glucose and glycosylated hemoglobin levels. ATP III guidelines suggest that physicians provide specific recommendations for moderate, sustained physical activity appropriate to the patient's physical status. Examples of moderate physical activity and ways to Table 3. Examples of Moderate Physical Activity for Healthy Adults Brisk walking (3 4 mph) for minutes Swimming laps for 20 minutes Bicycling for pleasure or transportation, 5 miles in 30 minutes Volleyball (noncompetitive) for 45 minutes Moderate lawn mowing (push a powered mower) for 30 minutes Home care heavy cleaning Basketball for minutes Golf pulling a cart or carrying clubs Social dancing for 30 minutes Reprinted from Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. September 2002; NIH publication Table 4. Ways to Incorporate More Physical Activity into the Day Walk more look for opportunities! Park farther away in parking lots near a mall so you have a longer walk Walk or bike if your designation is just a short distance away Walk up or down 1 2 flights of stairs instead of always taking the elevator Walk after work for 30 minutes before getting in the car and sitting in traffic Walk home from the train or bus take a longer route so it takes 20 minutes instead of 5 10 Walk with a colleague or friend at the start of your lunch hour for 20 minutes Do heavy house cleaning, push a stroller, or take walks with your children Exercise at home while watching television Go dancing or join an exercise program that meets several times per week If wheelchair bound, wheel yourself for part of every day in a wheelchair Reprinted from Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. September 2002; NIH publication S506 Vol. 5 (6A) June 2005
5 increase physical activity during normal daily activities are listed in Tables 3 and 4, respectively. 2 Besides diet and exercise, smoking cessation is important in reducing cardiovascular risk among atrisk patients who smoke. INTERVENTION: PHARMACOTHERAPY Low-density lipoprotein-lowering pharmacotherapy is considered (but may not always be required) in patients with LDL cholesterol 100 mg/dl or higher. 2 Therapy to address atherogenic dyslipidemia (ie, triglycerides 150 mg/dl and HDL cholesterol <40 mg/dl), defining characteristic of the metabolic syndrome, is initiated after the LDL treatment goal is achieved with therapeutic lifestyle changes or pharmacotherapy. Clinical trials of cholesterol-lowering drugs, primarily the statins and the fibrates, demonstrate their efficacy in primary prevention and secondary prevention of cardiovascular morbidity and mortality. For example, statin therapy significantly reduced the risk for major coronary events in the West of Scotland Coronary Prevention Study (WOSCOPS) 10 and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), 11 both of which are major primary-prevention trials. In WOSCOPS, patients (n = 6595; baseline LDL 192 mg/dl) were treated with pravastatin 40 mg/day or a placebo for up to 4.9 years. 10 Over the follow-up period, LDL cholesterol concentrations were decreased by 26% with the statin compared to a placebo. The risks of major coronary events were reduced by 31%, coronary mortality by 33%, and total mortality by 22%. The AFCAPS/TexCAPS study observed 6605 patients (baseline LDL 150 mg/dl) for up to 5 years during treatment with lovastatin (20 mg/40 mg daily) or a placebo. 11 Over the follow-up period, LDL cholesterol concentrations were decreased by 35% with the statin compared to a placebo, and the risk of a major coronary event was reduced by 37%. The difference between active treatment and placebo was not statistically significant with respect to reductions in coronary mortality and total mortality in this study. Secondary-prevention trials, including the Scandinavian Simvastatin Survival Study, 12 the Cholesterol and Recurrent Events Study, 13 and the Long-Term Intervention with Pravastatin in Ischemic Disease Study, 14 demonstrate reductions over followup periods of at least 5 years in recurrent myocardial infarction, coronary mortality, and stroke. The relationship between LDL cholesterol concentrations and coronary events in several major clinical studies of statins is illustrated in the Figure. 2 Fibrates and niacin have also been demonstrated effective in modifying dyslipidemia, and they can be added to statins to decrease triglyceride and HDL cholesterol concentrations. 2 The benefits of fibrates are illustrated by the results of the Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Interventional Trial (VA-HIT), 15 a double-blind, placebo-controlled, secondary-prevention study of patients with dyslipidemia whose baseline LDL concentrations were 100 to 120 mg/dl. Over a 5.1-year follow-up period, gemfibrozil (1200 mg/day) did not change LDL cholesterol levels as compared to Figure. Relationship Between LDL Cholesterol Concentrations and Coronary Events in Clinical Studies of Statins Major coronary event rate, % LIPID CARE Post-CABG 5 AFCAPS/TexCAPS LDL-C during trial 4S LRC-CPPT WOSCOPS 4S = Scandinavian Simvastatin Survival Study; AFCAPS/TexCAPS = Air Force/Texas Coronary Atherosclerosis Prevention Study; CARE = Cholesterol and Recurrent Events Study; LDL-C = low-density lipoprotein cholesterol; LIPID = Long-Term Intervention with Pravastatin in Ischaemic Disease; LRC-CPPT = Lipid Research Clinics Coronary Primary Prevention Trial; WOSCOPS = West of Scotland Coronary Prevention Study. Reprinted from Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. September 2002; NIH publication Advanced Studies in Medicine S507
6 placebo, but it increased HDL cholesterol concentrations by 6% and decreased triglyceride concentrations by 31%. These changes were associated with a 22% reduction in the incidence of nonfatal myocardial infarction and coronary heart disease death, a 22% reduction in coronary heart disease death, a 23% reduction in nonfatal myocardial infarction, and an 11% reduction in total mortality. These findings support the potential for additional cardiovascular risk reduction through increasing HDL cholesterol and decreasing triglycerides, even among patients with moderately elevated LDL cholesterol. A statin-niacin combination was also shown to be effective in the HDL Atherosclerosis Treatment Study. 16 Patients (n = 160) with coronary artery disease, low HDL, and normal LDL received simvastatin + niacin, antioxidant vitamins, simvastatin + niacin + antioxidant vitamins, or a placebo for up to 3 years. The results show that coronary artery stenosis progressed by 0.4% with simvastatin + niacin, 0.7% with simvastatin + niacin + antioxidants, and 1.8% with antioxidants as compared to 3.9% with placebo (P <.05 for both groups treated with simvastatin and niacin). The incidence of a cardiovascular event (ie, death, myocardial infarction, stroke, revascularization) was lowest with simvastatin + niacin (3%) followed by simvastatin + niacin + antioxidants (14%), antioxidants (21%), and a placebo (24%). The authors concluded that simvastatin + niacin markedly improves clinical and angiographic measures in patients with coronary heart disease with low HDL levels, but the use of antioxidant vitamins in these patients should be questioned. 16 In controlled clinical trials including VA-HIT, cardiovascular benefits of statins are often greater in subgroups of patients with components of the metabolic syndrome as compared to overall study populations defined primarily by elevated LDL cholesterol concentrations. 17 This observation underlines the importance of statin therapy for patients with the metabolic syndrome. Although statin therapy is well suited for these patients, monotherapy with a statin may not be sufficient for managing their mixed dyslipidemia. 17,18 Because the metabolic syndrome is associated with a constellation of lipid abnormalities including but not limited to LDL elevations, combination statin/fibrate therapy may be indicated. Combination therapy may more effectively target the mixed dyslipidemia occurring in the metabolic syndrome than monotherapy with statins, which most effectively target LDL cholesterol. The ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial should provide information germane to this issue. The ACCORD trial is comparing cardiovascular outcomes in patients with diabetes who were administered a statin alone (ie, simvastatin 20 mg) with those outcomes in patients who received a statin with a fibrate (ie, simvastatin 20 mg + fenofibrate 160 mg). The results of this study are expected to become available in approximately 4 years. Safety concerns have limited the use of fibrates such as gemfibrozil. 17 Other fibrates, such as fenofibrate, appear to have a better safety profile than gemfibrozil, especially in combination with a statin. Modified formulations of fenofibrate (145-mg tablet [Tricor] and 130-mg capsule [Antara]) have recently been introduced in the United States. These treatments, in conjunction with diet, are approved to reduce elevated LDL cholesterol, total cholesterol, and triglycerides and increase HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia and in patients with hypertriglyceridemia. In 4 randomized, double-blind, parallel-group, placebocontrolled studies involving patients with hypercholesterolemia and mixed dyslipidemia treated with fenofibrate at a dose equivalent to 145-mg tablet or placebo for 3 to 6 months, patients receiving fenofibrate at a dose equivalent to 145-mg tablet showed lower LDL cholesterol (-20.6% vs -2.2%), total cholesterol (-18.7% vs -0.4%), and triglycerides (-28.9% vs +7.7%) and increased HDL cholesterol (+11.0% vs +0.7%). 19 Fenofibrate at a dose equivalent to 145-mg tablet reduced serum triglycerides in 2 randomized, double-blind, placebo-controlled clinical trials in patients with hypertriglyceridemia. 19 Significant reduction in triglycerides with fenofibrate at a dose equivalent to 145-mg tablet versus placebo was observed in patients with baseline triglyceride levels of 350 to 499 mg/dl (-46.2% vs -0.5%) and in those patients with baseline triglyceride levels of 500 to 1500 mg/dl (-54.5% vs +7.2%). Fenofibrate capsule produces the same results at the equivalent dose of 130 mg daily. 20 Neither fenofibrate 145-mg tablet nor fenofibrate 130-mg capsule interacts with food, a property that may be associated with improved patient compliance. Therefore, these modified formulations S508 Vol. 5 (6A) June 2005
7 can be taken without regard to meals. The lack of interaction of fenofibrate 130-mg capsule with food is demonstrated by the results of the TRIMS (Triglyceride Reduction in Metabolic Syndrome) study, a randomized, double-blind, placebo-controlled trial that assessed the efficacy of fenofibrate 130-mg capsule with and without food in patients with hypertriglyceridemia and the metabolic syndrome. 21 Patients with the metabolic syndrome and hypertriglyceridemia received fenofibrate 130-mg capsule with food (n = 40), without food (n = 40), or placebo for 8 weeks in conjunction with a low-fat diet. The results show that fenofibrate 130-mg capsule significantly reduced triglycerides and improved other lipid parameters versus placebo regardless of whether it was given with food. The magnitude of effect of fenofibrate 130-mg capsule on lipid parameters was nearly identical when it was given with food versus without food. At the end of the treatment period, triglyceride levels were 295 mg/dl in the group given fenofibrate 130-mg capsule with food and 296 mg/dl in the group given fenofibrate 130-mg capsule without food compared to 474 mg/dl in placebo-treated patients (P <.001; both groups receiving fenofibrate 130-mg capsule vs placebo). Calculated LDL cholesterol levels at the end of treatment were 134 mg/dl in each of the groups receiving fenofibrate 130-mg capsule compared to 114 mg/dl in the placebo group. HDL cholesterol levels at the end of treatment were 40 mg/dl in the group receiving fenofibrate 130-mg capsule with food and 41 mg/dl in the group receiving fenofibrate 130-mg capsule without food compared to 35 mg/dl in placebo-treated patients. CONCLUSIONS The validation of the metabolic syndrome as a clinical entity provides the clinician with an opportunity to identify at-risk patients who previously may not have been identified as candidates for risk-modifying interventions. Management of the metabolic syndrome should be governed by the strategies of early recognition, early initiation of lifestyle modification and pharmacotherapy, and, when necessary, the aggressive use of combination therapy to achieve treatment goals. Early identification and intervention of the metabolic syndrome can improve a patient's cardiovascular and metabolic outcomes. REFERENCES 1. The metabolic syndrome. American Diabetes Association Web site. Available at: Accessed January 29, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. September 2002; NIH publication US Preventive Services Task Force. Screening for lipid disorders in adults. Summary of recommendations, Available at: Accessed February 4, McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139: McLaughin T, Allison G, Abbasi F, et al. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism. 2004;53: Grundy SM, Pasternak R, Greenland P, et al. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34: Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106: Pitt B, Rubenfire M. Risk stratification for the detection of preclinical coronary artery disease. Circulation. 1999;99: Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333: Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335: Advanced Studies in Medicine S509
8 14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339: Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Group. N Engl J Med. 1999;341: Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345: Tenenbaum A, Fisman EZ. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins, or both? Cardiovasc Diabetol. 2004;3:10. Available at: Accessed February 4, Davidson MH. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004;93:3C-11C. 19. Tricor (fenofibrate tablets) Complete Prescribing Information. North Chicago, Illinois: Abbott Laboratories; November Antara (fenofibrate capsules) Complete Prescribing Information. Liberty Corner, New Jersey: Reliant Pharmaceuticals; The TRIMS (Triglyceride Reduction in Metabolic Syndrome) Study. Data on file, Reliant Pharmaceuticals; S510 Vol. 5 (6A) June 2005
Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationTHE PAST DECADE HAS WITnessed
SPECIAL COMMUNICATION Clinical Goals and Performance Measures for Cholesterol Management in Secondary Prevention of Coronary Heart Disease Thomas H. Lee, MD James I. Cleeman, MD Scott M. Grundy, MD Clayton
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationROUNDTABLE DISCUSSION: IMPLICATIONS OF ADULT TREATMENT PANEL (ATP) III GUIDELINES AND EMERGENT RESEARCH FOR CLINICAL PRACTICE
ROUNDTABLE DISCUSSION: IMPLICATIONS OF ADULT TREATMENT PANEL (ATP) III GUIDELINES AND EMERGENT RESEARCH FOR CLINICAL PRACTICE The following are excerpts from a roundtable discussion with faculty co-chairs
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More information8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome.
Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome Diagnostic Criteria (3/5) Metabolic Syndrome Key Facts JAN BRIONES DNP, APRN, CNP FAMILY NURSE PRACTITIONER Abdominal
More informationPRIMARY PREVENTION OF ATHEROSCLEROTIC VASCULAR DISEASE
ATHEROSCLEROSIS PRIMARY PREVENTION OF ATHEROSCLEROTIC VASCULAR DISEASE Preventing atherosclerosis before it leads to death and disability should now be possible using lifestyle modification and drugs where
More informationWhen it comes to the FIELD study, what is...is
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney
More informationThe past decade has witnessed major strides in the
AHA/ACC Scientific Statement Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations A Statement for Healthcare Professionals From the American Heart Association and the American
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationLipid Management Step Therapy Criteria with Medical Diagnoses Option*
Lipid Management Step Therapy Criteria with Medical Diagnoses Option* * Medical diagnoses are required for implementation of this option. Program may be implemented with the following options: Option One
More informationAttainment of Combined Optimal Lipid Values With the Use of Niacin
www.medscape.com Attainment of Combined Optimal Lipid Values With the Use of Niacin Has AIM-HIGH Closed the Book on This Debate? Tyan Thomas Clin Lipidology. 2012;7(4):389-396. Abstract and Introduction
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationCARDIOMETABOLIC SYNDROME
CARDIOMETABOLIC SYNDROME Prof. Gerald Yonga FESC, FACC Dept of Medicine, Aga Khan University East Africa Introduction Years after the term metabolic syndrome was first coined, controversy continues over
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More informationLipid Management: Tools for Getting to the Goal
... PRESENTATIONS... Lipid Management: Tools for Getting to the Goal Based on a presentation by James M. McKenney, PharmD Presentation Summary The treatment of hypercholesterolemia in the United States
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationHow much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis
Point of View How much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis José Luiz da Costa Vieira, Vera Lúcia Portal, Emílio
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationHigh risk strategies for atherosclerosis
Clinica Chimica Acta 286 (1999) 31 45 High risk strategies for atherosclerosis * Paul Cullen FRCPI, Gerd Assmann FRCP Institute of Clinical Chemistry and Laboratory Medicine and Institute of Arteriosclerosis
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More information